技术指标
指标
数值
方向
MACD(12,26,9)
0.014
买入
RSI(14)
58.708
中性
STOCH(KDJ)(9,3,3)
70.537
中性
ATR(14)
0.066
低波动
CCI(14)
151.405
买入
Williams %R
36.364
买入
TRIX(12,20)
0.443
卖出
StochRSI(14)
55.163
卖出
搜索
Biofrontera Inc
BFRI添加自选
1.170USD
-0.060-4.88%
收盘 07-31 16:00（美东）报价延迟15分钟
13.89M总市值
亏损市盈率 TTM
关键数据
1.210今开
1.230最高
433.14K成交量
亏损市盈率 TTM
2.50市盈率动
--股息TTM
3.65%换手率
1.230昨收
1.145最低
363.47K成交额
亏损市盈率静
2.29市净率
0.00%股息率 TTM
-53.58%ROA
1.19052周最高
0.75量比
-17.76M净利润
11.87M总股本
-0.9689每股收益TTM
0.85Beta
-339.04%ROE
0.53652周最低
6.90%振幅
79.02%毛利率
13.89M总市值
4.41回报/风险
4.93%风险率
TradingKey Biofrontera Inc股票评分
单位: USD 更新时间: 2026-07-31操作建议
Biofrontera Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名75/155位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.00。中期看，股价处于平稳状态。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Biofrontera Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Biofrontera Inc亮点
亮点风险
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
业绩高增长
公司营业收入稳步增长，连续3年增长22.41%
业绩增长期
公司处于发展阶段，最新年度总收入41.70M美元
估值低估
公司最新PE估值-1.21，处于3年历史低位
机构减仓
最新机构持股2.75M股，环比减少9.14%
分析师目标
根据
2
位分析师
买入
评级
6.000
目标均价
+412.82%
涨幅空间
Biofrontera Inc新闻
即将为您带来更多新闻，敬请期待。。。
收益预测
分析师评级
根据
2
位分析师
买入
评级
6.000
目标均价
+412.82%
涨幅空间
强力买入
买入
持有
卖出
强力卖出
同行比较
160
总数
6
中位数
9
平均值
公司名称
评级分布
分析师数
Biofrontera Inc
BFRI
2
安进
AMGN
38
Biogen Inc
BIIB
38
礼来
LLY
34
艾伯维
ABBV
33
辉瑞
PFE
32
1
2
3
...
32
技术指标
移动平均线
指标
数值
方向
MA5
1.146
买入
MA10
1.112
买入
MA20
1.114
买入
MA50
1.007
买入
MA100
0.991
买入
MA200
0.934
买入
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Biofrontera Inc简介
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
公司代码BFRI
公司Biofrontera Inc
CEOLuebbert (Hermann)
网址https://www.biofrontera-us.com/
公司股东
相关品种
热门品种
常见问题
Biofrontera Inc(BFRI)的当前股价是多少？
Biofrontera Inc(BFRI)的当前股价是 1.17。
Biofrontera Inc的股票代码是什么？
Biofrontera Inc的股票代码是BFRI。
Biofrontera Inc股票的52周最高点是多少？
Biofrontera Inc股票的52周最高点是1.19。
Biofrontera Inc股票的52周最低点是多少？
Biofrontera Inc股票的52周最低点是0.54。
Biofrontera Inc的市值是多少？
Biofrontera Inc的市值是13.89M。
现在Biofrontera Inc(BFRI)的股票是买入、持有还是卖出？
根据分析师评级，Biofrontera Inc(BFRI)的总体评级为买入，目标价格为6.00。
Biofrontera Inc(BFRI)股票的每股收益（EPS TTM）是多少
Biofrontera Inc(BFRI)股票的每股收益（EPS TTM）是-1.04。